Home > Boards > US Listed > Biotechs > Amarin Corp. PLC ADS (AMRN)

North. Thx I know that .

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Whalatane Member Profile
 
Followed By 50
Posts 11,286
Boards Moderated 0
Alias Born 06/13/11
160x600 placeholder
Amarin Launches True To Your Heart, a Campaign to Educate People on Persistent Cardiovascular Risk GlobeNewswire Inc. - 1/13/2020 6:00:10 AM
Amarin Provides Update to Preliminary 2019 Results and Further Details on 2020 Outlook GlobeNewswire Inc. - 1/7/2020 6:00:10 AM
Amarin to Present at 38th Annual J.P. Morgan Healthcare Conference GlobeNewswire Inc. - 1/6/2020 6:00:10 AM
VASCEPA® Approved in Canada to Reduce the Risk of Cardiovascular Events GlobeNewswire Inc. - 1/2/2020 6:00:10 AM
Amarin Receives FDA Approval of VASCEPA® (icosapent ethyl) to Reduce Cardiovascular Risk PR Newswire (US) - 12/13/2019 6:14:00 PM
Amarin Receives FDA Approval of VASCEPA® (icosapent ethyl) to Reduce Cardiovascular Risk GlobeNewswire Inc. - 12/13/2019 4:49:07 PM
European Medicines Agency Accepts for Review Marketing Authorization Application for Amarin’s Icosapent Ethyl (Vascepa®) f... GlobeNewswire Inc. - 12/2/2019 6:00:10 AM
Amarin Highlights Key REDUCE-IT®-Related Data Presented at American Heart Association 2019 Scientific Sessions GlobeNewswire Inc. - 11/18/2019 5:30:00 PM
Amarin’s John Thero Awarded EY Entrepreneur of The Year® 2019 Life Sciences National Award GlobeNewswire Inc. - 11/18/2019 12:15:12 PM
Amarin Announced FDA Advisory Committee Voted Unanimously (16-0) to Recommend Approval of Vascepa® (icosapent ethyl) Capsule... GlobeNewswire Inc. - 11/14/2019 5:34:37 PM
Amarin Corporation plc (NASDAQ:AMRN) Stock Trading Halted Today for Scheduled FDA Advisory Committee Review of sNDA Seeking N... GlobeNewswire Inc. - 11/14/2019 6:59:25 AM
New Analysis Shows Icosapent Ethyl (Vascepa®) Is Cost Effective and Offers Rare Finding of Better Outcomes at Lower Healthca... GlobeNewswire Inc. - 11/11/2019 1:19:57 PM
REDUCE-IT® USA Results, in Prespecified Subgroup Analyses of Landmark REDUCE-IT Global Study, Showed Robust Cardiovascular R... GlobeNewswire Inc. - 11/11/2019 6:30:48 AM
Amarin to Present at the Jefferies 2019 London Healthcare Conference GlobeNewswire Inc. - 11/11/2019 5:00:00 AM
Amended Current Report Filing (8-k/a) Edgar (US Regulatory) - 11/5/2019 5:29:19 PM
Quarterly Report (10-q) Edgar (US Regulatory) - 11/5/2019 6:37:28 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 11/5/2019 6:31:38 AM
Amarin Reports Third Quarter 2019 Financial Results and Provides Update on Operations GlobeNewswire Inc. - 11/5/2019 5:00:00 AM
Seven Data Presentations Relevant to Vascepa® (Icosapent Ethyl) Capsules and Persistent Cardiovascular Risk to be Presented ... GlobeNewswire Inc. - 11/4/2019 6:00:00 AM
Amarin to Report Third Quarter 2019 Results and Host Conference Call on November 5, 2019 GlobeNewswire Inc. - 10/24/2019 4:30:05 PM
On Watch this Week with Near-Term Potential Catalysts InvestorsHub NewsWire - 10/21/2019 8:00:00 AM
Independent Drug-Pricing Assessment Finds Vascepa® (icosapent ethyl) Cost-Effective as an Adjunct to Statins in Treating Pat... GlobeNewswire Inc. - 10/17/2019 9:49:02 AM
Amarin to Participate in the Cantor Global Healthcare Conference GlobeNewswire Inc. - 9/23/2019 4:15:00 PM
National Lipid Association’s New Position Statement on Use of Icosapent Ethyl in High and Very-High-Risk Patients Recognize... GlobeNewswire Inc. - 9/16/2019 6:00:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 9/12/2019 6:14:02 AM
Whalatane   Tuesday, 09/17/19 01:29:53 AM
Re: north40000 post# 214725
Post # of 242262 
North. Thx I know that .
What I was looking for were concise responses . I am not able to send a 5 page argument . I'm limited to a set number of letters in my email responses thru Kaiser .

Poster Atom has directed me to some concise responses ....on Amarin's web site
Kiwi

PS. I just saw your links ...thx ...will go thru them

PPS. in listening to Dr Bhatt .....he describes R-IT as over 60% secondary prevention and the rest primary prevention . The primary prevention group being mainly diabetics with one additional risk factor .

My Cardiologist's argument is that if he were to prescribe Vascepa to me .. he would only prescribe it if I were a
1) Secondary prevention patient. ..ie prior MI etc
2) Diabetic with 1 additional risk factor

That is different from my understanding of the NLA statement ...which was clinical ASCVD , Tg's over 135 , optimal statin therapy .
Can you be clinical ASCVD without having a prior event ?...my understanding is that you can >
Whats your opinion

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist